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A neonatal intensive care unit outbreak was caused by
a strain of methicillin-resistant Staphylococcus aureus pre-
viously found in the community (ST45-MRSA-IV). Fifteen
infected neonates were identified, 2 of whom died. This out-
break illustrates how a rare community pathogen can rap-
idly spread through nosocomial transmission. 
S
ince 1998, strains of highly virulent, community-asso-
ciated, methicillin-resistant Staphylococcus aureus
(CA-MRSA), which are distinct from the typical nosoco-
mial MRSA (NA-MRSA), have been reported (1,2). CA-
MRSA is susceptible to numerous antimicrobial agents, in
contrast to the multidrug-resistant (MDR) NA-MRSAphe-
notype, because it carries the staphylococcal cassette chro-
mosome mec (SCCmec) type IV or V, rather than type I, II
or III (3,4). The high virulence of CA-MRSA has been
linked to Panton-Valentine leukocidin (PVL), a virulence
factor found in most of these strains (2,5). We report a
nosocomial MRSA outbreak in a neonatal intensive-care
unit (NICU), by a non-MDR MRSA strain that carries the
SCCmec type IV.
The Outbreak
Sheba Medical Center is a 1,500-bed, tertiary care hos-
pital in which ≈10,000 infants are delivered annually.
MDR MRSA is endemic in the hospital, constituting
50%–60% of all S. aureus isolates, while non-MDR
MRSA has been observed in only 2 cases in the last 5
years. The premature neonatal department admits 500 pre-
mature neonates annually, nearly 100% of whom are born
in the hospital. The department contains ≈45 beds: 12–14
level 3 NICU beds in a single large space, 15 intermediate-
intensive beds in a separate room, and 18 additional beds
in 2 additional rooms. The NICU is separated by a corridor
from the rest of the department. The nurse/patient ratio in
the NICU is 1:3–1:5. 
During October 2003, the microbiology laboratory
identified MRSA blood isolates from 2 neonates in the
NICU that were atypically susceptible to erythromycin,
clindamycin, gentamicin, rifampicin (rifampin), trimetho-
prim-sulfamethoxazole (TMP-SMX), and ofloxacin
(therefore designated non-MDR MRSA). Because of the
rarity of such a phenotype in this institution, a retrospec-
tive search for all S. aureus clinical isolates from the pre-
mature neonatal department since 1998 was undertaken by
using computerized laboratory data. 
Atotal of 14 neonatal infections with non-MDR MRSA
were discovered during this period. A cluster of 12 cases
was observed from October 2002 to December 2003 (des-
ignated the outbreak period), while 2 sporadic cases were
isolated from January 1, 1998, to September 31, 2002, the
preoutbreak period (Figure 1). The incidence of all S.
aureus infections was 15.2 per 1,000 hospitalized neonates
in the preoutbreak period, while during the outbreak peri-
od, it increased to 27.7 (p = 0.032). The incidence of non-
MDR MRSA was 1.4 cases per 1,000 hospitalized
neonates in the preoutbreak period; the rate increased to
18.5 cases per 1,000 hospitalized neonates (p < 0.0001)
during the outbreak period (Table). 
The first case of the cluster occurred 15 months after the
second sporadic case. This case was in a 690-g female
neonate of 25 weeks’ gestational age, hospitalized in the
NICU since birth. A non-MDR MRSA was isolated from
eye discharge on her 22nd day of life, and she recovered
with no antimicrobial drug treatment. The next 11 case-
patients (Figure 2A) were also hospitalized in the NICU
since birth; 9 were bacteremic and had signs of sepsis, 4 had
sputum isolates (2 of these patients had pneumonia), 2 died,
and 1 death was attributable to the infection. Thirteen of 14
neonates were treated with vancomycin for periods ranging
from 6 to 48 days; 2 were treated with vancomycin and
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Figure 1. Incidence of Staphylococcus aureus infections in prema-
ture neonatal ward, 1998–2004. MSSA, methicillin-susceptible
Staphylococcus aureus; MDR, multidrug resistant; MRSA, methi-
cillin resistant S. aureus.rifampicin. None of the patients had perinatal infections,
and the median age when infection was diagnosed was 30
days (range 11–115 days). Eleven patients had extremely
low birth weight (range 568–2,440 g, median 810 g), and
12 had low gestational age (range 23–35 weeks, median 25
weeks). All patients had indwelling devices (mechanical
ventilation for 11 to 74 days, central lines and total par-
enteral nutrition for 7–38 days). Four neonates had previ-
ous major surgery, and all neonates had at least 1 of several
complications of prematurity (respiratory distress syn-
drome, bronchopulmonary dysplasia, intraventricular
hemorrhage, retinopathy of prematurity). 
An infection control intervention was initiated on
December 5, 2003. Screening for S. aureus carriage was
performed by nasal and umbilical sampling of all hospital-
ized neonates (N = 30; all were sampled on day 1) and
nasal sampling of all the department healthcare workers (N
= 114 [47 nurses, 30 physicians, 37 other healthcare work-
ers]; 85% were sampled within 5 days). Swabs were
streaked onto a differential media (CHROMagar plates,
HyLabs, Rehovot, Israel) and incubated for 24 to 48 hours
at 35°C. Suspicious colonies were then conventionally
identified. Oxacillin resistance was determined according
to National Committee for Clinical Laboratory Standards
recommendations (6) and was verified by polymerase
chain reaction (PCR) for the presence of mecA (1). Eight
patient-unique, non-MDR S. aureus blood isolates from
the previous year were also available for analyses. 
In this point-prevalence surveillance, a non-MDR
MRSAwas isolated from 3 neonates with previous clinical
isolates and from 4 newly recognized carriers. Thus, 7
(23.3%) of 30 hospitalized neonates were carriers. In addi-
tion, 2 (1.7%) healthcare workers, both nurses (4.3% of
nurses), carried this strain; MDR MRSA was not isolated.
Methicillin-susceptible S. aureus was carried by 28.1% of
healthcare workers and was not isolated from any of the
neonates. 
Pulsed-field gel electrophoresis (PFGE) was per-
formed, as previously described (7), on 13 unique isolates
from 11 neonates and 2 nurses. A single identical outbreak
strain was identified by the PFGE pattern (Figure 2B). All
non-MDR MRSA were found to be SCCmec type IV by a
modification of the method described by Oliveira (8). By
using multilocus sequence typing (MLST) (9), the out-
break strain was classified as ST45-MRSA-IV. PCR
screening of the outbreak strain for 25 virulence factor
genes was performed as described by Jarraud et al. (10).
MLST and PCR of virulence factors were performed on 8
outbreak isolates. Virulence factors commonly found in
CA-MRSA, lukS-PV-lukF-PV encoding PVL components
S and F, γ-hemolysin variant (hlg-v), and agr type 3, were
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Figure 2. A) Nosocomial transmission of non-multidrug-resistant
(MDR) methicillin-resistant Staphylococcus aureus (MRSA) in the
premature neonatal ward. Dotted lines represent hospitalization
until first non-MDR MRSA isolation. Solid lines represent hospital-
ization after first non-MDR MRSA isolation until discharge. B)
pulsed-field gel electrophoresis of MRSA outbreak isolates; lanes
1–10: ST45-MRSA-IV outbreak strains isolated from neonates;
lanes 11–12: ST45-MRSA-IV outbreak strains isolated from nurs-
es; lane 13: ST45 methicillin-susceptible S. aureus strain from a
community survey; lane 14: common nosocomial MRSA strain
ST5-MRSA-II.not detected in the outbreak strain. The outbreak strain was
positive for enterotoxin gene cluster (egc),  γ-hemolysin
(hlg), and agr type 1 and had similar PFGE and MLST
results as the major methicillin-susceptible S. aureus
(MSSA) strain found in the community served by this hos-
pital. The outbreak strain was identical to the CA-MRSA
that is rarely isolated in healthy carriers in Israel (11).
Moreover, this strain differed from the MDR MRSA
strains that are commonly isolated in this medical center
(Figure 2B).
After initial surveillance, all case-patients were isolated
and cohorted, appropriate hand hygiene practices were
reinforced for healthcare workers, and all neonates were
bathed with diluted (1:10) chlorhexidine gluconate 4%
once daily for 3 consecutive days. Nasal mupirocin was
implemented 3 times per day for 5 consecutive days for all
carriers. These regimens were well tolerated with no
adverse events.
Three weeks after the first surveillance and interven-
tion, a second surveillance was conducted in the NICU and
intermediate neonatal care unit. No new cases were identi-
fied. Of the 7 carriers, only 4 were still hospitalized. Of
these, 2 continued to carry the outbreak strain, and 2 were
successfully decolonized. The 2 carriers were decolonized
after a second course of a similar regimen (chlorhexidine
bath followed by mupirocin administration). 
The 2 colonized nurses were sampled twice, 1 week
apart, and were found to be persistent carriers of the out-
break strain. They were instructed about good hand
hygiene practices, and nasal mupirocin was recommended
for 5 days. One nurse cleared her nasal non-MDR MRSA
after mupirocin treatment and acquired a new strain of
MSSA 2 weeks later. The other refused mupirocin treat-
ment and persistently carried the outbreak strain for 8
weeks. During this period, despite our instructions, she
continued to work until she went on maternity leave.
Before she returned to work 12 weeks later, she was
decolonized by using nasal mupirocin. In a 7-month fol-
low-up, no new cases of non-MDR MRSAwere identified
(Figure 1).
Conclusions
This report documents a nosocomial outbreak of a non-
MDR, PVL-negative MRSA strain, ST45-IV, in a NICU.
This strain is clearly distinct from the NA-MRSAstrains in
this medical center, but it is identical to a CA-MRSAstrain
previously isolated in the community (in 0.5% of S. aureus
carriers) and is nearly identical to the major MSSA strain
circulating in this community (11). We hypothesize that the
outbreak strain evolved in the community and penetrated
into the NICU. Two previous reports of possible CA-
MRSA in NICUs have been reported; however, neither
characterized the alleged pathogen genetically (12,13).
The outbreak strain reported here is similar to CA-
MRSA strains described in Europe, the United States, and
Australia in that it is susceptible to many antimicrobial
drugs and carries the SCCmec type IV (2,5). However, this
strain is distinct from those strains because it lacks the
PVL components S and F, as well as other virulence fac-
tors. Indeed, skin and soft-tissue infections typically
described as caused by CA-MRSA(1,2) were not observed
in any of the neonates in this outbreak. 
MRSA outbreaks in NICUs have been reported to be
difficult to contain (12,14). Only implementation of
aggressive infection control measures, frequently com-
bined with mupirocin treatment, has been successful in
controlling such outbreaks. The outbreak described here
was similarly contained by implementing a multifaceted
infection control intervention. Since all the measures were
undertaken simultaneously, we cannot define which of the
measures was the most important.
We assume that the primary source of this outbreak was
either a parent of the index patient or a carrier nurse.
Because of a low ratio of nurses to neonates in the NICU
and the high contact rate each nurse had with neonates in
that facility, we could not trace specific contact patterns or
perform a case-control study to further investigate this out-
break. 
The difficulties encountered in implementing proper
infection control measures are demonstrated by the fact that
1 healthcare worker continued to be engaged in patient care
for 8 weeks, despite continued colonization by the outbreak
strain, against our advice to her supervisors. Fortunately,
this action did not result in persistence of the outbreak.
This outbreak illustrates the penetration of a communi-
ty pathogen into the hospital, where nosocomial transmis-
sion, particularly in an intensive care setting, may rapidly
spread the pathogen. The susceptibility of newborns, cou-
pled with insufficient infection control measures and inad-
equate nurse-to-patient ratio, contributed to this outbreak.
We call for specific attention to the possibility of “reverse
penetration” of community MRSA strains becoming noso-
comial pathogens. 
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